- Acute leukemia
- Chronic myeloid leukemia (CML)
- Chronic myelomonocytic leukemia (CMML)
- Essential thrombocytopenia (ET)
- Leukemia
- Myelodysplastic syndrome (MDS)
- Myelofibrosis
- Polycythemia vera
Selina M. Luger, MD
About me
- Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
My education and training
- McGill UniversityMedical School
- Penn Presbyterian Medical CenterResidency
- University of Pennsylvania Health SystemFellowship
Spoken languages
Reviews
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Hematology, 1994
- AML Hub, International
- American Society of Clinical Oncology, National
- American Society of Hematology, National
- Children's Oncology Group (COG) DSMC-A, National
- ECOG-ACRIN cancer research group (ECOG-ACRIN), National
- Geneva Translational Oncology Program (GTOP), International
- National Cancer Institute (NCI), National
- Royal College of Physicians & Surgeons of Canada, National
- Society of Hematologic Oncology (SOHO), National
- Stichting Hemato-Oncologie voor Volswassenen Nederland (HOVON), International
- University of Chicago Comprehensive Cancer Center, National
- University of Connecticut Naeg Cancer Center, National
- Blood cancer care
- Recognized annually in Philadelphia Magazine's Top Docs issue from 2018 through 2025
All conditions and treatments
Research
Publications
Ferthio R, Bruno XJ, Garfall AL, Cohen AD, Kapur S, Lai CE, Luger SM, Stadtmauer EA, Vogl DT, Waxman A, Susanibar-Adaniya SP. Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia , Haematologica: 2026
Zugmaier G, Goekbuget N, Luger S, Litzow M, Cario G, Locatelli F. Depletion of CD19-positive B-cells and dexamethasone premedication may result in immune suppression in patients with B-precursor acute lymphoblastic leukemia after consolidation treatment with blinatumomab , Haematologica: 2026
Zhong X, Roberts KG, Wei H, Sun Z, Montefiori LE, Kumar A, Iacobucci I, Baviskar P, Gao Q, Pölönen P, Pruett-Miller SM, Schreiber RM, Chang TC, Zhang W, Lei S, Rampersaud E, Fan Y, Wu G, Mattison RJ, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Abou Mourad Y, Shami PJ, Baer MR, Asch AS, O'Dwyer KM, Hall A, Liedtke M, Bergeron J, Wood BL, Pratz KW, Dinner SN, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, Podoltsev NA, DeAngelo DJ, Patel S, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Tallman MS, Yang JJ, Luger SM, Paietta E, Litzow MR, Mullighan CG. Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study , Blood: 2026
Tremblay D, Chen L, Sun Z, Ganzel C, Fernandez H, Foran J, Arber DA, Lazarus H, Zhang Y, Paietta E, Bennett JM, Rowe J, Litzow M, Tallman M, Atallah E, Luger S. Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials , Haematologica: 2026
Silva WF, Yin J, Liedtke M, Claxton DF, Fulton N, Giri S, Malnassy G, Mrózek K, Paietta E, Mullighan CG, Galinsky I, Bogart JA, Grecula JC, Kennedy L, Larson RA, Stone RM, Uy GL, Luger SM, Advani AS, Stock W. Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance) , Blood Adv, 10: 2026,5487-5491
Kharfan-Dabaja MA, Kumar A, Pemmaraju N, Murthy H, Al Malki M, Bashir Q, Bubis J, Lane AA, Nishihori T, de Lima M, Gangat N, Jamy O, Konopleva M, Luger S, Savani B, Sweet K, Wang E, Carpenter PA, Hamadani M. Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy , Transplant Cell Ther: 2026
Boulter AC, Li Y, Wang X, Zheng DJ, Pratz K, Luger S, Aplenc R, Getz KD. Primary Cardioprotection in Frontline Anthracycline Therapy for Adult Hematologic Cancers , JAMA Netw Open, 9: 2026,e2630536
Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Récher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul;22(16):1913-1924. doi: 10.1080/14796694.2026.2689464. Epub 2026 Jul 11. PMID: 42434847; PMCID: PMC13390524. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia , Future Oncology, 22: 2026
Lee J, Sun R, Kume K, Robinson ME, Cheng Z, Cosgun KN, Ma N, Hurtz C, Geng H, Luger SM, Litzow MR, Paietta E, Chen J, Vaidehi N, Müschen M. Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia , Sci Signal, 19: 2026,eadw5054
Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A. Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL , Blood Adv, 10: 2026,593-603